Carrie A. Schinstock, M.D.

Why did you choose to study clinical and translational research?

I really enjoy my clinical practice of taking care of kidney transplant patients from around the country. The problem is that many of my patients have chronic antibody-mediated rejection leading to allograft failure, and I do not have any effective therapy for this type of rejection.

Being a clinical and translational researcher allows me to better understand their disease process with the goal of ultimately developing therapy for them.

What type of research are you doing?

We are characterizing donor-specific anti-HLA antibody in renal transplant recipients and correlating this with clinical and histologic outcomes to determine whether certain donor-specific antibody characteristics are associated with allograft dysfunction and loss.

We are also developing novel methodology to assess the effect of donor-specific antibody in the allograft by adapting laser capture microdissection techniques coupled with gene expression studies to renal allografts.

Why Mayo Clinic?

Why not Mayo Clinic? The resources available for a young faculty member excited about doing clinical and translational research at Mayo are amazing. Specifically in the transplant center, there is a culture of team science and spirit of collaboration.

I also have access to the state of the art from a basic science perspective, while also being able to take care of patients. This is the optimal environment for translational research.

What are you looking forward to as a KL2 scholar?

I am looking forward to collaborating with translational research experts outside of my field of study. This will not only give me a new perspective on my own research projects and career trajectory but also be an outstanding networking opportunity for me.

I am also really looking forward to having time to hone skills that will help me be successful throughout my research career, including hypothesis generation, study design, statistical skills, grant writing and paper writing.